FOXO Technologies 3Q 2026: Revenue $7M — 10-Q Summary
FOXO Technologies reported 3Q 2026 revenue of $7M, up 97.38% YoY, with earnings shifting from a loss to income. Growth was driven by higher RCHI revenue, including Medicare adjustments and rate changes. The Life Science Services segment saw revenue increase to $406,953. The Grifols acquisition remains pending regulatory approvals and financing.
How this was made

The 30-second read
Why it matters
Traders can use the disclosed drivers of revenue and operating income to reassess near-term earnings power, while monitoring the unresolved Grifols acquisition as a potential catalyst or drag depending on regulatory and financing progress.
Market read
A quarterly filing summary with concrete financial direction and identifiable drivers, plus a pending M&A-related overhang.
What to watch
The labs segment ceased R&D under a technology license agreement, and the Grifols acquisition remains pending, both of which could affect forward earnings quality and timing.
Background
The piece summarizes FOXO Technologies’ 3Q 2026 Form 10-Q, including segment performance and a pending acquisition update.
Ticker impact
FOXO’s 3Q 2026 10-Q summary reports revenue up 97.38% YoY and improved earnings, driven by higher RCHI Medicare-related revenue and swing-bed volume.
Likely upward bias as investors price in stronger Medicare-linked revenue, tempered by risk that the Grifols acquisition timing slips.
The article provides specific directional financial improvements and identifies key drivers (RCHI Medicare adjustments, rate changes, swing-bed volume), while also noting the Grifols acquisition has not closed and regulatory/financing items remain outstanding.
Market effects
Highlights how Medicare cost-report adjustments, rate changes, and swing-bed volume can materially swing healthcare services revenue and margins.
No specific regional impact described.
Primarily US Medicare reimbursement dynamics; limited global spillover.
Counterpoint
Revenue growth may be partly driven by Medicare cost-report adjustments and rate changes, which can be non-recurring or subject to future reconciliation.
Key entities
- companyFOXO Technologies Inc.
Subject of the 10-Q summary, reporting sharp YoY revenue growth and improved earnings, with segment and acquisition updates.
- companyGrifols
Counterparty in a proposed four-center acquisition that has not closed due to regulatory authorizations and financing remaining outstanding.



